Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 May 23;25(11):5684.
doi: 10.3390/ijms25115684.

MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program

Kimberly A Lewis  1 , Benjamin M Stroebel  1 , Li Zhang  2 , Bradley Aouizerat  3 , Aras N Mattis  4 , Elena Flowers  1   5
Affiliations
Randomized Controlled Trial

MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program

Kimberly A Lewis et al. Int J Mol Sci. .

Abstract

The Diabetes Prevention Program (DPP) randomized controlled trial demonstrated that metformin treatment reduced progression to type 2 diabetes (T2D) by 31% compared to placebo in adults with prediabetes. Circulating micro-ribonucleic acids (miRs) are promising biomarkers of T2D risk, but little is known about their associations with metformin regimens for T2D risk reduction. We compared the change in 24 circulating miRs from baseline to 2 years in a subset from DPP metformin intervention (n = 50) and placebo (n = 50) groups using Wilcoxon signed rank tests. Spearman correlations were used to evaluate associations between miR change and baseline clinical characteristics. Multiple linear regression was used to adjust for covariates. The sample was 73% female, 17% Black, 13% Hispanic, and 50 ± 11 years. Participants were obese, normotensive, prediabetic, and dyslipidemic. Change in 12 miR levels from baseline to 2 years was significantly different in the metformin group compared with placebo after adjusting for multiple comparisons: six (let-7c-5p, miR-151a-3p, miR-17-5p, miR-20b-5p, miR-29b-3p, and miR-93-5p) were significantly upregulated and six (miR-130b-3p, miR-22-3p, miR-222-3p, miR-320a-3p, miR-320c, miR-92a-3p) were significantly downregulated in the metformin group. These miRs help to explain how metformin is linked to T2D risk reduction, which may lead to novel biomarkers, therapeutics, and precision health strategies.

Keywords: diabetes prevention program; diabetes risk; metformin; microRNA; post-transcription.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Box plots of mean change in MicroRNA expression level by treatment group for microRNAs significant after adjustment for multiple comparisons. Note: MiR-93a-5p was borderline statistically significant after adjusting for multiple comparisons (FDR = 0.059).
Figure 2
Figure 2
Correlation plot featuring only miRNAs significant after adjustment for multiple comparisons and baseline clinical characteristics. Cells with p > 0.05 are omitted. Color coding represents the Spearman rank correlation coefficient with red indicating an inverse association and blue indicating a positive association.
See this image and copyright information in PMC

Update of

References

    1. Centers for Disease Control and Prevention . National Diabetes Statistics Report, 2020. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; Atlanta, GA, USA: 2020.
    1. Aroda V.R., Knowler W.C., Crandall J.P., Perreault L., Edelstein S.L., Jeffries S.L., Molitch M.E., Pi-Sunyer X., Darwin C., Heck-man-Stoddard B.M., et al. Metformin for diabetes prevention: Insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia. 2017;60:1601–1611. doi: 10.1007/s00125-017-4361-9. - DOI - PMC - PubMed
    1. Diabetes Prevention Program Research Group Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2019;42:601–608. doi: 10.2337/dc18-1970. - DOI - PMC - PubMed
    1. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., Nathan D.M., Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002;346:393–403. doi: 10.1056/NEJMoa012512. - DOI - PMC - PubMed
    1. Madsen K.S., Chi Y., Metzendorf M.-I., Richter B., Hemmingsen B. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2019;12:CD008558. doi: 10.1002/14651858.CD008558.pub2. - DOI - PMC - PubMed

Publication types